Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 11/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635740 | 0.86 | CSNK1E (0.43) | HDAC8CSNK1EPRMT5WDR77 | |
| SCHEMBL12635744 | 0.86 | CSNK1E (0.43) | HDAC8CSNK1EPRMT5WDR77 | |
| SCHEMBL495855 | 0.85 | HDAC8 (0.50) | HDAC8CSNK1EPRMT5WDR77 | |
| Hydrochloric Acid SCHEMBL496040 | 0.83 | HDAC8 (0.51) | HDAC8CSNK1EPRMT5WDR77 | |
| SCHEMBL12671626 | 0.81 | CSNK1E (0.38) | HDAC8CSNK1ESLC18A3 | |
| SCHEMBL496299 | 0.80 | SLC18A3 (0.52) | CSNK1ESLC18A3 | |
| SCHEMBL496300 | 0.80 | SLC18A3 (0.52) | CSNK1ESLC18A3 | |
| Hydrochloric Acid SCHEMBL496575 | 0.79 | SLC18A3 (0.51) | SLC18A3 | |
| Hydrochloric Acid SCHEMBL496576 | 0.79 | SLC18A3 (0.51) | SLC18A3 | |
| SCHEMBL496381 | 0.79 | PRMT5 (0.56) | HDAC8PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283346-B2 | Human immunodeficiency virus protease inhibitors | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY (US) | 2012-10-09 | — | — | US | disclosed |
| US-20110112068-A1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS | THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112068-A1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS | SERPINB1, PREP, TMPRSS15 | HDAC8 1103/4885CSNK1E 1630/4885SLC18A3 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.